EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immune checkpoint inhibitors in hepatocellular carcinoma: A review of current clinical trials

Adriana C Gamboa, David A Kooby, Shishir K Maithel iD, T Clark Gamblin iD

Journal of Surgical Oncology · 2024

DOI: 10.1002/jso.27545 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Adriana C Gamboa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with a poor prognosis due to advanced disease presentation or recurrence despite curative‐intent resection. Since the approval of sorafenib in 2007, few systemic therapies offered a significant improvement in treatment outcomes. Over the last 3 years, however, rapid advancements in the field of immunotherapy have led to approval of checkpoint inhibitors in 2020 for use in advanced HCC. Since then, a few other clinical trials have shown promising results in the adjuvant and neoadjuvant setting. The objective of this review is to summarize data from existing clinical trials evaluating the use of systemic immune checkpoint inhibitors in HCC and to follow the natural evolution of this development across the metastatic, adjuvant, and neoadjuvant landscapes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansImmune Checkpoint InhibitorsSorafenibTreatment OutcomeImmunotherapy

Stichwörter der Autor:innen

hepatocellular carcinomaimmune checkpoint inhibitorsimmunotherapytumor microenviroment

Substanzen

Immune Checkpoint InhibitorsSorafenib

Autor:innen und Institutionen

  • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Surgery, Division of Surgical Oncology, Winship Cancer Institute, Atlanta, Georgia, USA.
  • Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

ORCID-Profile: Shishir K Maithel, T Clark Gamblin

Zitieren

APA

Gamboa, A. C., Kooby, D. A., Maithel, S. K., & Gamblin, T. C. (2024). Immune checkpoint inhibitors in hepatocellular carcinoma: A review of current clinical trials. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27545

Vancouver

Gamboa AC, Kooby DA, Maithel SK, Gamblin TC. Immune checkpoint inhibitors in hepatocellular carcinoma: A review of current clinical trials. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27545

BibTeX
@article{Gamboa2024,
  author = {Gamboa, Adriana C and Kooby, David A and Maithel, Shishir K and Gamblin, T Clark},
  title = {Immune checkpoint inhibitors in hepatocellular carcinoma: A review of current clinical trials},
  journal = {Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1002/jso.27545}
}
Kostenlos starten →